Medtronic says its AccuRhythm AI algorithm technology is the winner of seven awardsth Voted “Best New Monitoring Solution” in the annual MedTech Breakthrough Awards program. AccuRhythm AI is an artificial intelligence algorithm that improves the accuracy of heart rhythm event data from Medtronic LINQ II Insertable Cardiac Monitors (ICMs), enabling physicians to better care for people with abnormal heart rhythms. Medtronic’s AI technology stood out among nearly 4,000 nominations worldwide.
MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, runs the MedTech Breakthrough Awards program. The LINQ family of Insertable Cardiac Monitors (ICMs) provides continuous, long-term monitoring for patients at high risk of heart rhythm abnormalities who experience rare symptoms such as dizziness, palpitations, fainting, and chest pain. Ongoing management.
“We are thrilled to receive the MedTech Breakthrough Award for technology that has such a large impact on patients and helps clinicians focus on the most relevant cardiac events,” said Cardiovascular Diagnostics and Services Business. said Stacey Churchwell, vice president and general manager of Within the Cardiac Rhythm Management Operating Unit. “We look forward to building on this AI technology for future enhancements across her ICMs in the LINQ family.”
Medtronic will introduce AccuRhythm AI algorithms to patients and clinicians in Australia, European countries, the United States and New Zealand in 2022 to improve the accuracy of the information physicians receive so they can better treat their patients. Two AI algorithms – specialized for the most common ICM false alarms, atrial fibrillation (AF) and pause (Asystole) — It has been shown to reduce the number of false alarms by as much as 84% and save clinicians approximately 319 hours of laboratory testing time per year (per 200 LINQ II patients).
Enhancements to the AF algorithm in the LINQ II ICM are expected to further reduce false alarms in AF and reduce review time in the clinic.
Medtronic also announced FDA market clearance to apply the AccuRhythm AI algorithm to Reveal LINQ ICM, the predecessor of LINQ II ICM, via cloud-based updates. Medtronic expects the AccuRhythm AI algorithm to reduce approximately 89.5% of AF false alarms and 80.2% of pause false alarms by Reveal LINQ, while retaining true alerts at 98.2% and 99.9% rates, respectively. Since his 2014, the provider has used the Reveal LINQ ICM to care for her more than 750,000 patients worldwide. The AccuRhythm AI update for Reveal LINQ ICM is also available in Europe.
“The addition of AccuRhythm AI to the thousands of Reveal LINQ ICMs currently implanted in patients around the world will help the many hospitals and clinics that still regularly use this device for patient monitoring. It’s important because it helps reduce the data load on our customers,” said Alan Cheng, M.D., Deputy Director. President and CMO of the Cardiac Rhythm Management Operating Unit, part of Medtronic’s cardiovascular portfolio.
Medtronic developed the AccuRhythm AI platform and algorithms using a proprietary, diverse, unbiased database of over one million ECG heart rhythm episodes. Medtronic will continue to automatically apply AccuRhythm AI in the cloud to facilitate seamless patient care. The AccuRhythm AI algorithm in Reveal LINQ ICM and the updated AF algorithm in LINQ II will be available later this year.
